[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Ausper Biopharma Co., Ltd.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":184},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,41,65,77,102,123,145,166],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100053235","phase-2-study-of-ahb-171-in-chronic-hepatitis-b-participants-100053235",false,"NCT07630727","Study of AHB-171 in Chronic Hepatitis B Participants","An Open-label Phase II Clinical Study to Evaluate the Efficacy and Safety of AHB-171 Injection in Participants With Chronic Hepatitis B","Inclusion Criteria:\n\n* Able to fully understand and sign the informed consent form (ICF).\n* Male or female participants, aged 18-65 years (inclusive).\n* Body mass index (BMI) meeting the predefined eligibility range.\n* Chronic hepatitis B (CHB) participants with HBsAg or HBV DNA positivity for ≥6 months at screening.\n* At screening, participants meeting predefined ranges of HBsAg, HBV DNA, and ALT according to prior nucleos(t)ide analogue (NA) treatment history (stable prior treatment or treatment-naive), and meeting corresponding prior antiviral treatment duration requirements.\n* Adopt effective contraceptive measures as required\n\nExclusion Criteria:\n\n* History of any severe systemic disease or malignancy other than chronic HBV infection which, in the opinion of the investigator, makes the subject unsuitable for study participation.\n* Prior history of solid organ or hematopoietic stem cell transplantation.\n* History of any other liver disease that the investigator considers unsuitable for trial.History of autoimmune disease or diseases with potential immune activation risk.\n* History or presence of hepatic decompensation at screening.\n* History of primary liver cancer, or diagnosis\u002Fsuspected liver cancer at screening.\n* Imaging or histological evidence of significant liver fibrosis or cirrhosis within 12 months prior to screening, or a liver stiffness measurement indicative of significant fibrosis or cirrhosis at screening. Major trauma or major surgery within 12 weeks prior to screening\n* History of severe allergies (e.g., to ≥2 allergens) or severe allergy to any component of the study drug, or in the opinion of the investigator, makes the subject unsuitable for participation.\n* Severe infection requiring intravenous anti-infective therapy within 2 weeks prior to screening (excluding chronic HBV infection).\n* History of drug abuse, or alcoholism.\n* Blood donation or blood loss exceeding the specified volume within 12 weeks prior to screening, or planned blood donation during the trial period.\n* Use of immunosuppressants, immunomodulators, cytotoxic drugs, or biologics within 6 months prior to screening.\n* Use of any oligonucleotide drugs or interferon therapy within 12 months prior to screening.\n* Vaccination within 4 weeks prior to screening, or planned vaccination during the trial period.\n* Presence of tattoos, active skin diseases, or other conditions that may interfere with subcutaneous drug administration or observation of injection site reactions.\n* Clinically significant abnormal electrocardiogram (ECG) at screening.\n* Tested positive for HIV，HCV or active syphilis infection.\n* Uncontrolled hypertension at screening.\n* Clinically significant abnormal laboratory test as specified in protocol at screening.\n* Currently participating in another clinical trials, or within the washout period.\n* Any other condition or factor which, in the opinion of the investigator, makes the subject unsuitable for trial participation.","ALL","18 Years","65 Years",{"count":20,"type":21},138,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","The study adopts an open-label, multiple-dose design and aims to evaluate the efficacy and safety of AHB-171 Injection after multiple doses in treatment-naïve (HBeAg-negative\u002Fpositive) and nucleos(t)ide analogue (NA)-treated (HBeAg-negative) participants with chronic hepatitis B (CHB)",[27],"Hepatitis B, Chronic (CHB)","RECRUITING","2026-07-10",{"date":31,"type":32},"2026-07-13","ACTUAL",{"date":34,"type":32},"2026-06-24",{"date":36,"type":21},"2029-05-31",{"name":38,"class":39},"Ausper Biopharma Co., Ltd.","INDUSTRY",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":48,"targetDuration":4,"studyType":22,"phases":50,"briefSummary":51,"conditions":52,"keywords":54,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":64},"100643778","phase-2-a-study-to-evaluate-ahb-137-injection-in-treatment-nave-participants-with-chronic-hepatitis-b-100643778","NCT07635186","A Study to Evaluate AHB-137 Injection in Treatment-naïve Participants With Chronic Hepatitis B","A Randomized, Double-blind, Placebo-controlled, Multicenter Phase 2 Clinical Study to Evaluate the Efficacy and Safety of AHB-137 Injection in Treatment-naïve Participants With Chronic Hepatitis B.","Inclusion Criteria:\n\n* Volunteer to participate and sign the informed consent form, and are willing to complete the study in accordance with the requirements of the protocol.\n* Aged 18-65 years (including boundary values).\n* Body mass index between the range of 18-32 kg\u002Fm2 (inclusive boundary values).\n* HBsAg or HBV DNA positive for ≥ 6 months at screening and no antiviral treatment with interferon or nucleoside analogue.\n* HBsAg and HBV DNA values met protocol requirements at screening.\n* ALT \\\u003C 3xULN at screening.\n* Use highly effective contraception as required.\n\nExclusion Criteria:\n\n* Uncontrolled and stable clinically significant abnormalities other than a history of chronic HBV infection.\n* Participants with other clinically significant liver diseases, previous\u002Fcurrent manifestations of hepatic decompensation, and a history of extrahepatic diseases that may be related to HBV immune status.\n* Any serious infection other than chronic hepatitis B infection requiring intravenous anti-infective therapy within 1 month prior to randomization.\n* Hepatitis C virus (HCV) infection or \\\u003C 12 months from cure at screening (HCV RNA positive within 12 months), human immunodeficiency virus (HIV) positive at screening, and syphilis positive (treponema pallidum antibody positive).\n* Significant fibrosis or cirrhosis, or liver stiffness value (LSM) \\> 9.0 kPa at screening.\n* Participants with confirmed or suspected liver cancer who have a history of malignancy within the past 5 years or are undergoing assessment for a possible malignancy.\n* Laboratory test results do not meet the criteria.\n* Prior\u002Fcurrent autoimmune disease, history of vasculitis, or presence of signs, symptoms, or laboratory tests of underlying vasculitis.\n* Fridericia ' s formula corrected QT interval (QTcF) ≥ 450 msec for male participants and ≥ 470 msec for female participants at screening.\n* Allergic to AHB-137 ingredients, or history of drug allergy or other allergies.\n* Major trauma or major surgery within 3 months prior to screening, or planned surgery during the trial.\n* Participants are participating in another clinical trial or failing to wash out as required.\n* Current use or use of any immunosuppressive medication (e.g. prednisone) within 3 months prior to screening, except for short courses (≤ 2 weeks) or use of topical\u002Finhaled steroids;Those who have used immunomodulators within 3 months prior to screening;Those who have used cytotoxic drugs within 6 months prior to screening;History of vaccination within 1 month prior to screening or a live vaccination plan during the trial.\n* Participants that require regular long-term anticoagulants.\n* Abnormal thyroid function.\n* Participants that have received any antisense oligonucleic acid, siRNA, capsid assembly modulator (CAM) antiviral drug used to treat chronic hepatitis B.\n* Any other circumstances or conditions in which, in the opinion of the investigator, the participant is inappropriate for participation in this trial.",{"count":49,"type":21},320,[24],"This study is a randomized, double-blind, placebo-controlled, multicenter phase 2 study to assess the efficacy and safety of AHB-137 injection in treatment-naïve participants with chronic hepatitis B.",[53],"Chronic Hepatitis B",[53],"NOT_YET_RECRUITING","2026-06-03",{"date":58,"type":32},"2026-06-09",{"date":60,"type":21},"2026-06-20",{"date":62,"type":21},"2028-06-20",{"name":38,"class":39},2,{"id":66,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":67,"targetDuration":4,"studyType":22,"phases":68,"briefSummary":25,"conditions":69,"keywords":4,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":76,"locationsCount":40},"100638668",{"count":20,"type":21},[24],[27],"2026-06-02",{"date":72,"type":32},"2026-06-05",{"date":74,"type":21},"2026-07-15",{"date":36,"type":21},{"name":38,"class":39},{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":84,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":85,"targetDuration":4,"studyType":22,"phases":87,"briefSummary":89,"conditions":90,"keywords":92,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":40},"100632248","phase-1-a-phase-i-clinical-study-of-ahb---171-in-healthy-participantshp-and-chronic-hepatitis-b-chb-participants-100632248","NCT07511218","A Phase I Clinical Study of AHB - 171 in Healthy Participants(HP) and Chronic Hepatitis B (CHB) Participants","A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of AHB - 171 Injection in Healthy Participants (HP) and Chronic Hepatitis B(CHB) Participants","Inclusion Criteria:\n\n* Healthy Participants:\n* Male or female participants, aged 18-55 years old (inclusive);\n* Body mass index between 18.0 and 28.0 kg\u002Fm\\^2 (inclusive);\n* Laboratory safety tests during the screening period, 12-lead electrocardiogram (ECG), abdominal ultrasound, thyroid ultrasound, chest anteroposterior position, etc., are assessed by the investigatoras normal or abnormal without clinical significance;\n* Female participants of childbearing potential must not be pregnant or lactating, must have a negative pregnancy test at screening, and must agree to use effective contraceptive methods and refrain from donating eggs from screening until 6 months after the last dose of the study drug.\n* Male participants must agree to use highly effective contraceptive methods (to ensure effective contraception for their female partners of childbearing potential) and refrain from donating sperm from screening until 6 months after the last dose of the study drug. Liver and kidney function tests meet the requirements at the time of screening.\n* CHB Participants:\n* Male or female participants, aged 18-65 years old (inclusive);\n* Body mass index between 18.0 and 32.0 kg\u002Fm\\^2 (inclusive);\n* Participants who take effective contraceptive measures as required;\n* HBsAg \\> 100 IU\u002FmL and ≤ 3000 IU\u002FmL, and HBV DNA \\\u003C 100 IU\u002FmL at screening.\n* Have received stable treatment with NA for at least 6 months and stable on the same NA for at least 3 months before screening.\n\nExclusion Criteria:\n\n* Healthy Participants:\n* Currently participating in another study, or within 5 half-lives\u002F3 months of the last dose of a previous investigational product.\n* Presence diseases (cardiovascular, neurological, renal, immunological, metabolic, etc.) or malignant tumors.- Major surgery or severe trauma within the past 6 months.\n* Acute infection (e.g., influenza, gastroenteritis) within 14 days; vaccination within 28 days prior to screening.\n* Allergy to any investigational drug component.\n* Heavy Smoking (\\> 5 cigarettes\u002Fday); history of drug\u002Falcohol abuse; consumption of caffeine or alcohol within 48 hours before dosing.\n* Blood donation\u002Floss ≥400 mL or transfusion within 12 weeks, or plan to donate during study.\n* Abdominal skin issues that may affect drug injection\u002Fobservation.\n* Positive for HBV, HCV, HIV, or syphilis.\n* Clinically significant ECG abnormality or TdP risk factors.\n* Any condition judged unsuitable by investigator.\n* CHB Participants:\n* Currently participating in another study, or within 5 half-lives\u002F3 months of the last dose of a previous investigational product.\n* Presence of ascites, gastrointestinal bleeding, hepatic encephalopathy, or varices.\n* History or suspicion of hepatocellular carcinoma (HCC); AFP \\> 50 ng\u002FmL.\n* Diagnosed or Suspected cirrhosis within 12 months.\n* History of transplantation, autoimmune diseases, or severe systemic diseases (besides chronic HBV).\n* Use of ASO, siRNA (oligonucleotide therapies), or interferon within 12 months.\n* Major injury\u002Fsurgery within 6 months, planned surgery during study, or acute infection within 14 days.\n* Allergy to any investigational drug component.\n* Blood donation\u002Floss ≥400 mL or transfusion within 12 weeks, or plan to donate during study.\n* Abdominal skin issues that may affect drug injection\u002Fobservation.\n* Key laboratory result not suitable for clinical trial.\n* HIV, HCV, or active syphilis infection; uncured hepatitis A, D, or E.\n* Clinically significant ECG abnormality or TdP risk factors.\n* Any condition judged unsuitable by investigator.",true,{"count":86,"type":21},110,[88],"PHASE1","The goal of this clinical trial is to evaluate the safety, tolerability, immunogenicity and Pharmacokinetics (PK) characteristics of AHB-171 Injection in healthy participants (Part A) and participants with chronic hepatitis B (CHB, Part B), and assess its preliminary efficacy in CHB participants.",[91],"Chronic Hepatitis B Infection",[93],"Hepatitis B, Chronic","2026-05-27",{"date":96,"type":32},"2026-06-01",{"date":98,"type":32},"2026-04-13",{"date":100,"type":21},"2028-06-30",{"name":38,"class":39},{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":4,"eligibilityCriteria":108,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":109,"targetDuration":4,"studyType":22,"phases":111,"briefSummary":112,"conditions":113,"keywords":114,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":40},"100598290","phase-2-a-multicenter-study-of-ahb-137-injection-combined-with-other-hepatitis-b-drugs-100598290","NCT07069569","A Multicenter Study of AHB-137 Injection Combined With Other Hepatitis B Drugs","A Randomized, Open-Label, Multicenter Phase II Study to Evaluate the Efficacy and Safety of AHB-137 Injection in Combination With Hepatitis B Vaccine or Pegylated Interferon α-2b (Peg-IFN) in Participants With HBeAg-Negative Chronic Hepatitis B (CHB) Treated With Nucleos(t)Ide Analogue (NAs)","Inclusion Criteria:\n\n* Participants voluntarily participate in the study, and sign the Informed Consent Form (ICF) prior to screening, able to complete the study according to the protocol;\n* Aged between 18 and 65 years at the time of signing the ICF;\n* Body mass index (BMI) within the range of 18-30 kg\u002F m2;\n* HBeAg negative at screening;\n* HBsAg or HBV DNA positive for at least 6 months;\n* Continue antiviral therapy with a single nucleoside (t) ide analogue for more than 6 months prior to screening;\n* Alanine aminotransferase (ALT) ≤ 2 × upper limit of normal (ULN);\n* Effective contraception as required.\n\nExclusion Criteria:\n\n* Participants who are not eligible for treatment with Peg-IFN\u002Frecombinant hepatitis B vaccine;\n* Clinically significant abnormalities other than a history of chronic HBV infection;\n* Concomitant clinically significant other liver diseases;\n* Any serious infection other than chronic hepatitis B infection requiring intravenous anti-infective therapy within 1 month prior to screening;\n* HCV RNA positive, Human immunodeficiency virus (HIV) positive, syphilis positive;\n* Significant liver fibrosis or cirrhosis at screening, or a liver stiffness value (LSM) \\> 9.0 kPa;\n* Previous\u002Fcurrent manifestations of hepatic decompensation;\n* Diagnosis or suspicion of hepatocellular carcinoma, or alpha-fetoprotein concentration (AFP) ≥ 20 ng\u002FmL at screening;\n* Obviously abnormal laboratory test results;\n* History of vasculitis or presence of signs, symptoms, or laboratory tests of underlying vasculitis, and previous\u002Fcurrent other diseases that may be related to vasculitic conditions;\n* QT interval corrected for heart rate (Fridericia method) abnormal;\n* History of extrahepatic disease possibly related to HBV immune status;\n* Participants with a history of malignancy within the past 5 years or who are being evaluated for a possible malignancy;\n* Serious mental illness or history of serious mental illness prior to screening;\n* Suspected history of allergy to any component of the study drug, or allergic constitution;\n* Major trauma or major surgery within 3 months prior to screening, or planned surgery during the study;\n* Those who are participating in another clinical trial, or have not undergone a protocol-specified washout period prior to this study;\n* Current use or use of any immunosuppressive medication within 3 months prior to screening, with the exception of short courses (≤ 2 weeks) or use of topical\u002Finhaled steroids;Those who have used immunomodulators and cytotoxic drugs within 6 months prior to the first dose;Or a history of vaccination within 6 months prior to screening or a live vaccination plan during the trial;\n* Participants requiring regular long-term administration of anticoagulants or antiplatelet drugs;\n* Thyroid dysfunction;\n* Patients with uncontrolled epilepsy and other progressive neurological disorders;\n* Received any antisense oligonucleotides (ASO) or small molecule interfering ribonucleic acid (siRNA) drug;\n* Any other circumstance or condition that, in the opinion of the investigator, the participants are inappropriate for participation in the study.",{"count":110,"type":21},200,[24],"This is a randomized, open-label, multicenter phase II study to evaluate the efficacy and safety of AHB-137 injection in combination with other hepatitis B drugs in participants with HBeAg-negative CHB treated with NAs.",[53],[93],"2026-05-18",{"date":117,"type":32},"2026-05-20",{"date":119,"type":32},"2025-06-08",{"date":121,"type":21},"2028-01-15",{"name":38,"class":39},{"id":124,"slug":125,"hasResults":11,"nctId":126,"briefTitle":127,"officialTitle":127,"acronym":4,"eligibilityCriteria":128,"healthyVolunteers":84,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":129,"targetDuration":4,"studyType":22,"phases":131,"briefSummary":132,"conditions":133,"keywords":134,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":137,"lastUpdatePostDateStruct":138,"startDateStruct":140,"completionDateStruct":142,"leadSponsor":144,"locationsCount":40},"100640483","phase-1-a-clinical-study-evaluating-the-pharmacokinetic-characteristics-and-safety-of-ahb-137-injection-in-participants-with-mild-to-moderate-liver-dysfunction-and-those-with-normal-liver-function-100640483","NCT07600788","A Clinical Study Evaluating the Pharmacokinetic Characteristics and Safety of AHB-137 Injection in Participants With Mild to Moderate Liver Dysfunction and Those With Normal Liver Function.","Inclusion Criteria:\n\n* Voluntarily participate in the study, sign an informed consent form before the study and be able to complete the study according to the requirements of the protocol;\n* At the time of signing the informed consent form, male or female participants aged 18-65 years (including threshold values);\n* Body mass index meets the criteria;\n* Take effective contraceptive measures as required;\n* Participants with liver function impairment need to meet certain liver function assessments;\n* Participants with normal liver function should meet certain age, weight, and gender requirements to match those with liver function impairment, and should also undergo certain physical and laboratory tests.\n\nExclusion Criteria:\n\n* Diagnosed or suspected liver cancer participants who have undergone liver transplantation;\n* History of vasculitis or presence of signs and symptoms of potential vasculitis or laboratory tests;\n* Unstable control of hypertension or diabetes, progressive nervous system disease, history of immune related extrahepatic diseases, and unstable cardiac function;\n* Participants with a history of malignant tumors or undergoing malignant tumor assessment;\n* Screening for participants who have undergone significant trauma or surgery within the previous 3 months, as well as those who plan to undergo surgery;\n* Participants with thyroid dysfunction who are not suitable for inclusion in the study;\n* Allergic or allergic constitution to AHB-137;\n* Long term regular receipt of anticoagulant or antiplatelet drugs is required;\n* Those who have received any antisense oligonucleotide drugs or have been treated with siRNA drugs or interferon within the 12 months prior to screening;\n* Currently using or using any immunosuppressive medication within the past 3 months prior to screening, except for short-term use or the use of topical\u002Finhaled steroids; Individuals who have used immunomodulators and cytotoxic drugs within the 6 months prior to administration;\n* Those who have a history of vaccination or a plan to receive live vaccines within one month before administration, those who have used creatine containing fitness supplements 14 days before administration, and those who have used albumin 14 days before administration;\n* HIV, Syphilis positive ;\n* Those who are participating in another clinical trial and have not been eluted as required;\n* Positive results in urine drug screening and alcohol breath screening tests during screening;\n* Those who drink excessively and consume prohibited foods and beverages before administration;\n* Participants who have donated blood (or lost blood) ≥ 400 ml, received whole blood, or used red blood cell suspension within the past 3 months prior to screening; Individuals with a history of needle or blood dizziness, difficulty in blood collection, or intolerance to venipuncture blood collection;\n* Long term regular vigorous exercise or intense exercise within 48 hours before screening;\n* Any other circumstances or conditions that the researcher deems unsuitable for the subject to participate in this study;\n* Diseases that need to be excluded according to the merger plan for patients with abnormal liver function;\n* The laboratory test results do not meet the requirements of the protocol;\n* Participants with normal liver function who have a history of chronic liver disease or known liver or biliary abnormalities;\n* Participants with normal liver function who have used traditional Chinese medicine or other systemic medications with potential liver toxicity 14 days before administration;\n* Participants with normal liver function and abnormal QTcF values.",{"count":130,"type":21},32,[88],"A clinical study evaluating the pharmacokinetic characteristics and safety of AHB-137 injection in participants with mild to moderate liver dysfunction and those with normal liver function.",[53],[135,136],"Hepatitis B","Chronic","2026-05-14",{"date":139,"type":32},"2026-05-22",{"date":141,"type":21},"2026-05-15",{"date":143,"type":21},"2028-05-15",{"name":38,"class":39},{"id":146,"slug":147,"hasResults":11,"nctId":148,"briefTitle":149,"officialTitle":150,"acronym":4,"eligibilityCriteria":151,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":152,"targetDuration":4,"studyType":22,"phases":154,"briefSummary":155,"conditions":156,"keywords":157,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":159,"startDateStruct":161,"completionDateStruct":163,"leadSponsor":165,"locationsCount":40},"100603545","phase-2-a-study-to-evaluate-the-efficacy-and-safety-of-ahb-137-injection-in-participants-with-chronic-hepatitis-b-chb-100603545","NCT07137910","A Study to Evaluate the Efficacy and Safety of AHB-137 Injection in Participants With Chronic Hepatitis B (CHB)","An Open-label, Multicenter Phase II Clinical Trial to Evaluate the Efficacy and Safety of AHB-137 Injection in Participants With Chronic Hepatitis B Previously Treated With Nucleos (t) Ide Analogues (NA)","Inclusion Criteria:\n\n* Voluntarily participate in the study and sign the informed consent form;\n* 18-65 years of age (including boundary values) ;\n* Body mass index met the requirements;\n* Participants with CHB who are HBsAg or HBV DNA positive for at least 6 months;\n* Meet the relevant requirements for prior medications;\n* HBsAg and HBV DNA and liver function indicators meet the requirements;\n* Effective contraception as required;\n\nExclusion Criteria:\n\n* Uncontrolled and stable clinically significant abnormalities other than a history of CHB infection;\n* Associated liver disease;\n* Any serious infection other than CHB infection requires intravenous anti-infective therapy;\n* HCV RNA positive, HIV antibody positive, syphilis positive;\n* Abnormal laboratory results;\n* Diseases associated with vascular inflammatory conditions;\n* QT interval corrected heart rate (Fridericia method) abnormal;\n* History of malignancy or ongoing assessment of possible malignancy;\n* History of allergies, or allergic constitution;\n* Participants with recent major trauma or major surgery, or planning surgery;\n* Those who are participating in another clinical trial, or have not undergone a protocol-specified washout period prior to this study;\n* Prior\u002Fcurrent use of prohibited medications;\n* Inappropriate for participation in this trial as judged by the investigator.",{"count":153,"type":21},60,[24],"This study is an open-label, multicenter phase II clinical study to evaluate the efficacy and safety of AHB-137 injection in participants with CHB previously treated with NA.",[53],[93],"2026-05-01",{"date":160,"type":32},"2026-05-04",{"date":162,"type":32},"2025-09-04",{"date":164,"type":21},"2027-06-01",{"name":38,"class":39},{"id":167,"slug":168,"hasResults":11,"nctId":169,"briefTitle":170,"officialTitle":171,"acronym":4,"eligibilityCriteria":172,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":173,"targetDuration":4,"studyType":174,"phases":4,"briefSummary":175,"conditions":176,"keywords":177,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":178,"startDateStruct":179,"completionDateStruct":181,"leadSponsor":183,"locationsCount":64},"100604175","long-term-follow-up-study-to-evaluate-participants-with-chronic-hepatitis-b-chb-previously-treated-with-ahb-137-injection-100604175","NCT07146100","Long-term Follow-up Study to Evaluate Participants With Chronic Hepatitis B (CHB) Previously Treated With AHB-137 Injection","Prospective, Open-label, Multicenter Long-term Follow-up Study to Evaluate the Durability of Virologic Response in Participants With Chronic Hepatitis B Previously Treated With AHB-137 Injection","Inclusion Criteria:\n\n* Capable of giving informed consent.\n* Participants who have previously received at least one dose of AHB-137 and achieved the complete of partial response in the parent study without rescue medication and who maintained response until the End of Study (EoS) visit in their parent study.\n\nExclusion Criteria:\n\n* Participants who have\u002For are currently participating in another interventional clinical study since completing their treatment with AHB-137.\n* Suspected for cancer at screening or any condition required hospitalization during this study , or any condition which, in the opinion of the investigator or Medical Monitor, contraindicates their participation in this study.",{"count":110,"type":21},"OBSERVATIONAL","This study is a prospective, open-label, multicenter long-term follow-up study to evaluate the durability of virologic response in subjects with chronic hepatitis B previously treated with AHB-137 injection.",[53],[93],{"date":160,"type":32},{"date":180,"type":32},"2025-08-28",{"date":182,"type":21},"2030-01-01",{"name":38,"class":39},""]